« Back

AVI BioPharma to Present at the 29th Annual JPMorgan Healthcare Conference

01/06/11 8:04 AM EST

BOTHELL, WA, Jan 06, 2011 (MARKETWIRE via COMTEX) --

AVI BioPharma (NASDAQ: AVII), a developer of RNA-based drugs, announced today that the company is scheduled to present at the 29th Annual JPMorgan Healthcare Conference in San Francisco on Thursday, January 13, at noon Pacific Time. Chris Garabedian, AVI's president and CEO, will provide a company overview.

The conference presentation will be webcast live under the events section of AVI's website at www.avibio.com, and will be archived there following the presentation. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About AVI BioPharma AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, AVI's technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging its highly differentiated technology platform, AVI has built a pipeline of potentially transformative therapeutic agents, including a clinical stage Duchenne muscular dystrophy candidate and anti-infective candidates for influenza and hemorrhagic fever viruses. For more information, visit www.avibio.com.

SOURCE: AVI BioPharma, Inc. 


  
      






  


  
                                                                    

                                                                
                                                                
                                                                                                                                    

                                                                    
 

                                                                    
  
    
      
              
            
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.